Business
The telehealth company is also betting on secondary care.
Heading into 2024, companies face elevated interest rates, weak liquidity and no appetite from lenders for highly-leveraged capital structures.
The partners will initially launch in two clinics in Texas to provide patients with ALS access to virtual-first specialty care providers, including respiratory therapists.
The gastrointestinal surgery-focused company will use the funds to advance its endoluminal robotics technology for minimally invasive procedures.
The partners will leverage IBM’s foundation model technologies to help identify antibodies designed to target and neutralize various disease-causing agents or cells.
The company scored Class III Shonin clearance in Japan for its stroke platform and launched Rapid Edge Cloud, allowing continued AI access despite cloud connectivity.
The funds will be used to develop a comprehensive AI imaging model powered by imaging data to improve diagnostic precisions and early detection of conditions.
The company's product, Distill, uses machine learning algorithms and LLMs to perform administrative, clinical and research tasks that require chart review.
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
The healthcare system became a strategic investor in the Boston-based company and will utilize Laudio to enhance worker efficiency and engagement.